Supplements vergleichen

Approved regimen (Tymlos): 80 µg once daily by subcutaneous injection (abdomen), via a metered prefilled pen. This is a prescription drug — dose, duration and monitoring are set by a prescriber. The original 2-year cumulative-lifetime-use limit was REMOVED from the US label in 2021; duration is now an individualized clinical decision. There is no validated use outside osteoporosis fracture prevention.

Any time

Tymlos vorgefüllter Injektions-Pen (verschreibungspflichtig, über einen Arzt)

Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.

Any time

Subkutane einmal wöchentliche Injektion (Ozempic / Wegovy)

• Conditions with increased baseline osteosarcoma risk — Paget's disease of bone, unexplained elevated alkaline phosphatase, prior external-beam or implant skeletal radiation, open epiphyses (pediatric/young-adult), or bone metastases / skeletal malignancy
• Pre-existing hypercalcemia or conditions predisposing to hypercalcemia
• Pregnancy and breastfeeding (not for use)

• Digoxin
• Antihypertensives / drugs causing orthostatic hypotension
• Other PTH1-receptor agonists (teriparatide) and other anabolic agents

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Prior serious hypersensitivity to semaglutide or any GLP-1 receptor agonist

• Insulin and sulfonylureas
• Oral medications (general)
• Other GLP-1 receptor agonists